Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 799-804

  Abdelnour Berchtold, Etienne ^a   Cerantola, Yannick ^a   Roulin, Didier ^a   Dormond Meuwly, Anne ^a   Demartines, Nicolas ^a   Dormond, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

FOXO1; mTOR; Proliferation; Rapamycin

Indexed keywords

MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHR 3A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TRANSCRIPTION FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951044433     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Guertín DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
2. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
3. Easton JB and Houghton PJ: mTOR and cancer therapy. Oncogene 25: 6436-6446, 2006.
4. Shah OJ, Wang Z and Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656, 2004.
5. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL and Kwiatkowski DJ: Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through down-regulation of PDGFR. J Clin Invest 112: 1223-1233, 2003.
6. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW and Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006.
7. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP and Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223, 2004.
8. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
9. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
10. Accili D and Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117: 421-426, 2004.
11. Calnan DR and Brunet A: The FoxO code. Oncogene 27: 2276-2288, 2008.
12. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857-868, 1999.
13. Fu Z and Tindall DJ: FOXOs, cancer and regulation of apoptosis. Oncogene 27: 2312-2319, 2008.
14. 2-terminal kinase and Akt. Cancer Res 66: 212-220, 2006.
15. KIP1 promoter transactivation. Mol Cancer Res 3: 163-169, 2005.
16. Yang H, Zhao R, Yang HY and Lee MH: Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 24: 1924-1935, 2005.
17. 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110-2115, 1999.
18. Tang ED, Nunez G, Barr FG and Guan KL: Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746, 1999.
19. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005.
20. Vogt PK, Jiang H and Aoki M: Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4: 908-913, 2005
21. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB and Murli S: Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69: 510-517, 2009.